Pennsylvania is resuming its use of the Johnson & Johnson coronavirus vaccine.

The Pennsylvania Department of Health lifted its pause on the vaccine's administration throughout the state over the weekend.

On Friday, The Associated Press reported U.S. health advisers “urged” the resuming of the vaccine's use.

After the Johnson & Johnson vaccine began circulating, federal health officials uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the Johnson & Johnson shot. All were women, most under age 50. Three died, and seven remain hospitalized.

The Centers for Disease Control's Advisory Committee on Immunization Practices held an emergency meeting Friday, and determined the incidents are extremely rare.

“After a thorough review, federal experts have determined that the Johnson & Johnson vaccine is safe for all individuals,” said Pennsylvania's Acting Secretary of Health Alison Beam in a news release.

With the lifting of the pause, the shot will come with warnings that women and health workers would see in leaflets at vaccination clinics.

Out of the more than 7.6 million vaccine doses that have been administered in Pennsylvania, only 271,132 doses have been Johnson & Johnson.

“We continue to urge individuals to get vaccinated as soon as possible with any of the three vaccines available to them,” Beam said. “Getting vaccinated is essential as we work to prevent the spread of COVID-19, and also of serious and fatal complications due to the virus.”

In its own statement Friday, Johnson & Johnson acknowledged the condition that halted its vaccine's distribution.

“We will collaborate with health authorities around the world to educate health care professionals and the public to ensure this very rare event can be identified early and treated effectively,” said Paul Stoffels, Chief Scientific Officer of Johnson & Johnson, in the release.

According to health officials, people who have received the Johnson & Johnson vaccine and develop severe headache, chest pain, leg swelling, abdominal pain, tiny blood spots under the skin or excessive bruising within two weeks after vaccination should immediately contact their health care provider.

Despite the rare condition, Stoffels said the vaccine will remain a valuable tool in fighting the COVID-19 pandemic.

“As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere,” Stoffels said.

The Associated Press contributed to this report.